Merck exited the holiday weekend with some fireworks of its own, announcing three major programs on Tuesday all related to investments in finding ways to treat and prevent COVID-19.
The Kenilworth, NJ-based pharma giant said it had inked an agreement to acquire Austrian vaccine developer Themis, which has a COVID-19 candidate in preclinical development; develop another investigational vaccine with nonprofit IAVI, which also has a candidate in preclinical development; and develop and commercialize a clinical-stage antiviral candidate being advanced by Florida biotech Ridgeback Biotherapeutics.
Financial terms weren’t disclosed. Merck (NYSE: MRK) anticipates both vaccine candidates will enter human tests later… Read more »
UNDERWRITERS AND PARTNERS
